Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Gains Budget Increase In FY 2017… And Not Through Fees

Executive Summary

Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.

You may also be interested in...



Califf Warns US FDA Could Cut Services Without Budget Increase

The FDA commissioner indicates another flat budget or continuing resolution will not fund the mandatory pay increase already in place for staff.

FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal

User fee-heavy budget proposes appears to tie into Trump's broader deregulatory strategy; CDER and CBER would have to make cuts to non-user fee safety initiatives.

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel